Enterprise Value
59.69M
Cash
40.03M
Avg Qtr Burn
-9.639M
Short % of Float
8.12%
Insider Ownership
3.20%
Institutional Own.
31.22%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Iopofosine (CLR 131) Details Cancer, Lymphoma, Waldenstrom macroglobulinemia | NDA Submission | |
Iopofosine (CLR 131) Details Multiple myeloma, Cancer, High Refractory Multiple Myeloma | Phase 2 Data readout | |
Iopofosine (CLR 131) Details Cancer, B-cell lymphoma, Lymphoma | Phase 2 Update | |
Iopofosine (CLR 131) Details B-cell lymphoma, B-cell malignancies, Lymphoma, Cancer, Pediatric Sarcomas, High-grade Glioma
| Phase 1b Data readout | |
Iopofosine (CLR 131) + EBRT Details Head and neck cancer, Head and neck squamous cell carcinoma | Phase 1 Update |